Abbott, the global healthcare company, announced the launch of Navitor Vision in India for the treatment of patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk.

Abbott (ABT)'s new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation ...

Abbott Laboratories’ ABT structural heart line has received a major boost with the latest European regulatory approval for the company’s newest-generation transcatheter aortic valve implantation ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis ABBOTT PARK, Ill., May ...

Abbott Laboratories’ (NYSE: ABT) Navitor transcatheter aortic valve implantation (TAVI) system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or ...

ABBOTT PARK, Ill., Jan. 17, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant - The non-surgical Navitor TAVI system offers best-in-class deliverability and ...

ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, ...